Pediatric Laryngeal Coccidioidomycosis: A Case Series in an Endemic Region.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
21
7
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Laryngeal coccidioidomycosis is a rare but life-threatening manifestation of coccidioidomycosis. Data in children are sparse and limited to case reports. We conducted this study to review the characteristics of laryngeal coccidioidomycosis in children. We performed a retrospective review of patients ≤21 years of age with laryngeal coccidioidomycosis who were treated from January 2010 to December 2017. We collected demographic data, clinical and laboratory studies and patient outcomes. Five cases of pediatric laryngeal coccidioidomycosis were reviewed. All children were Hispanic and 3 were female. The median age was 1.8 years and the median duration of symptoms before diagnosis was 24 days. The most common symptoms included fever (100%), stridor (60%), cough (100%) and vocal changes (40%). Airway obstruction requiring tracheostomy and/or intubation for airway management was present in 80%. The most frequent location of lesions was the subglottic area. Coccidioidomycosis complement fixation titers were frequently low and culture/histopathology of laryngeal tissue was necessary to make a definitive diagnosis. All patients required surgical debridement and were treated with antifungal agents. None of the patients had recurrence during the follow-up period. This study suggests that laryngeal coccidioidomycosis in children presents with refractory stridor or dysphonia and severe airway obstruction. Favorable outcomes can be achieved with a comprehensive diagnostic work-up and aggressive surgical and medical management. With the rise in cases of coccidioidomycosis, physicians should have a heightened awareness regarding the possibility of laryngeal coccidioidomycosis when encountering children who have visited or reside in endemic areas with stridor or dysphonia.
Sections du résumé
BACKGROUND
Laryngeal coccidioidomycosis is a rare but life-threatening manifestation of coccidioidomycosis. Data in children are sparse and limited to case reports. We conducted this study to review the characteristics of laryngeal coccidioidomycosis in children.
METHODS
We performed a retrospective review of patients ≤21 years of age with laryngeal coccidioidomycosis who were treated from January 2010 to December 2017. We collected demographic data, clinical and laboratory studies and patient outcomes.
RESULTS
Five cases of pediatric laryngeal coccidioidomycosis were reviewed. All children were Hispanic and 3 were female. The median age was 1.8 years and the median duration of symptoms before diagnosis was 24 days. The most common symptoms included fever (100%), stridor (60%), cough (100%) and vocal changes (40%). Airway obstruction requiring tracheostomy and/or intubation for airway management was present in 80%. The most frequent location of lesions was the subglottic area. Coccidioidomycosis complement fixation titers were frequently low and culture/histopathology of laryngeal tissue was necessary to make a definitive diagnosis. All patients required surgical debridement and were treated with antifungal agents. None of the patients had recurrence during the follow-up period.
CONCLUSIONS
This study suggests that laryngeal coccidioidomycosis in children presents with refractory stridor or dysphonia and severe airway obstruction. Favorable outcomes can be achieved with a comprehensive diagnostic work-up and aggressive surgical and medical management. With the rise in cases of coccidioidomycosis, physicians should have a heightened awareness regarding the possibility of laryngeal coccidioidomycosis when encountering children who have visited or reside in endemic areas with stridor or dysphonia.
Identifiants
pubmed: 37200514
doi: 10.1097/INF.0000000000003961
pii: 00006454-202308000-00005
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
654-659Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Chiller TM, Galgiani JN, Stevens DA. Coccidioidomycosis. Infect Dis Clin North Am. 2003;17:41–57, viii.
California Department of Public Health. Epidemiologic summary of Valley Fever (Coccidioidomycosis) in California, 2019. Available at https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/ValleyFeverDataPublications.aspx
Centers for Disease Control and Prevention Valley Fever (Coccidioidomycosis) Statistics. Available at https://www.cdc.gov/fungal/diseases/coccidioidomycosis/index.html . Accessed December 1, 2022.
McCotter OZ, Benedict K, Engelthaler DM, et al. Update on the epidemiology of coccidioidomycosis in the United States. Med Mycol. 2019;57:S30–S40.
Fisher MC, Koenig GL, White TJ, et al. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis . Mycologia. 2002;94:73–84.
Galgiani JN, Ampel NM, Blair JE. Coccidioidomycosis. Clin Infect Dis. 2005;14:1217–1223.
Anstead GM, Graybill JR. Coccidioidomycosis. Infect Dis Clin North Am. 2006;20:621–643.
Rosenstein NE, Emery KW, Werner SB, et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995–1996. Clin Infect Dis. 2001;32:708–715.
Crum-Cianflone NF, Truett AA, Teneza-Mora N, et al. Unusual presentations of coccidioidomycosis: a case series and review of the literature. Medicine (Baltim). 2006;85:263–277.
Ghosh JS. Laryngeal coccidioidomycosis. JAMA. 1977;238:129.
Allen JE, Belafsky PC. Laryngeal coccidioidomycosis with vocal fold paralysis. Ear Nose Throat J. 2011;90:E1–E5.
Mumma CS. Coccidioidomycosis of the epiglottis. AMA Arch Otolaryngol. 1953;58:306–309.
Ward PH, Berci G, Morledge D, et al. Coccidioidomycosis of the larynx in infants and adults. Ann Otol Rhinol Laryngol. 1977;86:655–660.
Dudley JE. Coccidioidomycosis and neck mass “single lesion” disseminated disease. Arch Otolaryngol Head Neck Surg. 1987;113:553–555.
Singh H, Yast CJ, Gladney JH. Coccidioidomycosis with endolaryngeal involvement. AMA Arch Otolaryngol. 1956;63:244–247.
Gardner S, Seilheimer D, Catlin F, et al. Subglottic coccidioidomycosis presenting with persistent stridor. Pediatrics. 1980;66:623–625.
Benitz WE, Bradley JS, Fee WE Jr, et al. Upper airway obstruction due to laryngeal coccidioidomycosis in a 5-year-old child. Am J Otolaryngol. 1983;4:367–370.
Boyle JO, Coulthard SW, Mandel RM. Laryngeal involvement in disseminated coccidioidomycosis. Arch Otolaryngol Head Neck Surg. 1991;117:433–438.
Hajare S, Rakusan TA, Kalia A, et al. Laryngeal coccidioidomycosis causing airway obstruction. Pediatr Infect Dis J. 1989;8:54–56.
Platt MA. Laryngeal coccidioidomycosis. JAMA. 1977;237:1234–1235.
Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev. 1990;3:247–268.
Ampel NM. The diagnosis of coccidioidomycosis. F1000 Med Rep. 2010;2:2.
Kuberski T, Herrig J, Pappagianis D. False-positive IgM serology in coccidioidomycosis. J Clin Microbiol. 2010;48:2047–2049.
Blair JE, Coakley B, Santelli AC, et al. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia. 2006;162:317–324.
McHardy IH, Dinh BN, Waldman S, et al. Coccidioidomycosis complement fixation titer trends in the age of antifungals. J Clin Microbiol. 2018;56:e01318–e01318.
Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e112–e146.
Prabhu RM, Bonnell M, Currier BL, et al. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis. 2004;39:e74–e77.
Levy ER, McCarty JM, Shane AL, et al. Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series. Clin Infect Dis. 2013;56:1573–1578.